Spruce Biosciences, Inc. (NASDAQ:SPRB) has been given a consensus rating of “Buy” by the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $32.60.
Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Spruce Biosciences in a research note on Thursday, August 26th.
A number of institutional investors and hedge funds have recently bought and sold shares of SPRB. Wells Fargo & Company MN grew its stake in Spruce Biosciences by 223.6% during the second quarter. Wells Fargo & Company MN now owns 7,034 shares of the company’s stock valued at $79,000 after acquiring an additional 4,860 shares in the last quarter. New York State Common Retirement Fund grew its stake in Spruce Biosciences by 87.5% during the first quarter. New York State Common Retirement Fund now owns 6,000 shares of the company’s stock valued at $100,000 after acquiring an additional 2,800 shares in the last quarter. California State Teachers Retirement System grew its stake in Spruce Biosciences by 14.0% during the second quarter. California State Teachers Retirement System now owns 12,006 shares of the company’s stock valued at $135,000 after acquiring an additional 1,470 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in Spruce Biosciences during the first quarter valued at $207,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Spruce Biosciences in the 2nd quarter worth $218,000. 85.99% of the stock is owned by institutional investors.
Spruce Biosciences (NASDAQ:SPRB) last released its quarterly earnings results on Monday, August 9th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.05). Equities research analysts expect that Spruce Biosciences will post -2.12 EPS for the current fiscal year.
About Spruce Biosciences
Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH).
Featured Article: Why Invest in High-Yield Dividend Stocks?
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.